CC
ABBV icon

Cypress Capital’s AbbVie ABBV Stock Holding History

Cypress Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Sell
13,964
-894
-6% -$192K 0.95% 19
2026
Q1 		$3.23M Sell
14,858
-197
-1% -$43.7K 0.92% 19
2025
Q4 		$3.44M Buy
15,055
+192
+1% +$43.7K 0.96% 18
2025
Q3 		$3.44M Sell
14,863
-462
-3% -$94.1K 0.98% 16
2025
Q2 		$2.84M Sell
15,325
-209
-1% -$38.8K 0.83% 23
2025
Q1 		$3.25M Buy
15,534
+292
+2% +$56.8K 0.94% 17
2024
Q4 		$2.71M Sell
15,242
-156
-1% -$28.7K 0.77% 21
2024
Q3 		$3.04M Sell
15,398
-1,185
-7% -$221K 0.78% 20
2024
Q2 		$2.84M Sell
16,583
-4,588
-22% -$760K 0.71% 22
2024
Q1 		$3.86M Sell
21,171
-493
-2% -$85K 1.05% 15
2023
Q4 		$3.36M Buy
21,664
+214
+1% +$31.2K 0.96% 17
2023
Q3 		$3.2M Sell
21,450
-680
-3% -$99.8K 0.94% 15
2023
Q2 		$2.98M Buy
22,130
+471
+2% +$69.1K 0.86% 13
2023
Q1 		$3.45M Sell
21,659
-2,621
-11% -$401K 1.08% 12
2022
Q4 		$3.92M Buy
24,280
+75
+0.3% +$11.5K 1.23% 11
2022
Q3 		$3.25M Buy
24,205
+534
+2% +$76.6K 1.14% 11
2022
Q2 		$3.63M Sell
23,671
-3,327
-12% -$508K 0.52% 38
2022
Q1 		$4.38M Buy
26,998
+183
+0.7% +$26.6K 0.54% 38
2021
Q4 		$3.63M Buy
26,815
+279
+1% +$33K 0.41% 43
2021
Q3 		$2.86M Buy
26,536
+510
+2% +$58.3K 0.36% 45
2021
Q2 		$2.93M Buy
26,026
+1,895
+8% +$213K 2.86% 4
2021
Q1 		$2.61M Buy
24,131
+879
+4% +$94K 1.07% 13
2020
Q4 		$2.49M Sell
23,252
-351
-1% -$33.7K 1.13% 12
2020
Q3 		$2.03M Sell
23,603
-2,587
-10% -$244K 0.94% 13
2020
Q2 		$2.57M Buy
+26,190
New +$2.31M 1.14% 13

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cypress Capital's ABBV Position: Q2 2026 in Review

Cypress Capital reduced its AbbVie (ABBV) stake by 6% in Q2 2026, selling an estimated $192K and leaving 13,964 shares worth $3.51M. The position accounts for 0.95% of the portfolio, ranked #19.

Cypress Capital first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. The position peaked at $4.38M in Q1 2022. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Cypress Capital held 13,964 shares of AbbVie worth $3.51M as of Q2 2026.
  • Cypress Capital sold 894 AbbVie shares in Q2 2026, an estimated $192K.
  • AbbVie made up 0.95% of Cypress Capital's portfolio in Q2 2026, its #19 holding.
  • Cypress Capital first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • Cypress Capital's AbbVie position peaked at $4.38M in Q1 2022.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cypress Capital's 13F filing for Q2 2026, filed 17 Jul 2026.